Rajat Kalra1, Garima Arora2, Nirav Patel2, Rajkumar Doshi3, Lorenzo Berra4, Pankaj Arora2,5, Navkaranbir S Bajaj2,6,7. 1. From the Cardiovascular Division, University of Minnesota, Minneapolis, Minnesota. 2. Division of Cardiology, University of Alabama at Birmingham, Birmingham, Alabama. 3. Department of Cardiology, North Shore University Hospital, Northwell Health, Manhasset, New York. 4. Division of Anesthesia & Critical Care, Pulmonary Medicine, Massachusetts General Hospital, Boston, Massachusetts. 5. Section of Cardiology, Birmingham Veterans Affairs Medical Center, Birmingham, Alabama. 6. Division of Cardiovascular Medicine. 7. Department of Radiology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Abstract
BACKGROUND: Targeted temperature management (TTM) with therapeutic hypothermia is an integral component of postarrest care for survivors. However, recent randomized controlled trials (RCTs) have failed to demonstrate the benefit of TTM on clinical outcomes. We sought to determine if the pooled data from available RCTs support the use of prehospital and/or in-hospital TTM after cardiac arrest. METHODS: A comprehensive search of SCOPUS, Elsevier's abstract and citation database of peer-reviewed literature, from 1966 to November 2016 was performed using predefined criteria. Therapeutic hypothermia was defined as any strategy that aimed to cool post-cardiac arrest survivors to a temperature ≤34°C. Normothermia was temperature of ≥36°C. We compared mortality and neurologic outcomes in patients by categorizing the studies into 2 groups: (1) hypothermia versus normothermia and (2) prehospital hypothermia versus in-hospital hypothermia using standard meta-analytic methods. A random effects modeling was utilized to estimate comparative risk ratios (RR) and 95% confidence intervals (CIs). RESULTS: The hypothermia and normothermia strategies were compared in 5 RCTs with 1389 patients, whereas prehospital hypothermia and in-hospital hypothermia were compared in 6 RCTs with 3393 patients. We observed no difference in mortality (RR, 0.88; 95% CI, 0.73-1.05) or neurologic outcomes (RR, 1.26; 95% CI, 0.92-1.72) between the hypothermia and normothermia strategies. Similarly, no difference was observed in mortality (RR, 1.00; 95% CI, 0.97-1.03) or neurologic outcome (RR, 0.96; 95% CI, 0.85-1.08) between the prehospital hypothermia versus in-hospital hypothermia strategies. CONCLUSIONS: Our results suggest that TTM with therapeutic hypothermia may not improve mortality or neurologic outcomes in postarrest survivors. Using therapeutic hypothermia as a standard of care strategy of postarrest care in survivors may need to be reevaluated.
BACKGROUND: Targeted temperature management (TTM) with therapeutic hypothermia is an integral component of postarrest care for survivors. However, recent randomized controlled trials (RCTs) have failed to demonstrate the benefit of TTM on clinical outcomes. We sought to determine if the pooled data from available RCTs support the use of prehospital and/or in-hospital TTM after cardiac arrest. METHODS: A comprehensive search of SCOPUS, Elsevier's abstract and citation database of peer-reviewed literature, from 1966 to November 2016 was performed using predefined criteria. Therapeutic hypothermia was defined as any strategy that aimed to cool post-cardiac arrest survivors to a temperature ≤34°C. Normothermia was temperature of ≥36°C. We compared mortality and neurologic outcomes in patients by categorizing the studies into 2 groups: (1) hypothermia versus normothermia and (2) prehospital hypothermia versus in-hospital hypothermia using standard meta-analytic methods. A random effects modeling was utilized to estimate comparative risk ratios (RR) and 95% confidence intervals (CIs). RESULTS: The hypothermia and normothermia strategies were compared in 5 RCTs with 1389 patients, whereas prehospital hypothermia and in-hospital hypothermia were compared in 6 RCTs with 3393 patients. We observed no difference in mortality (RR, 0.88; 95% CI, 0.73-1.05) or neurologic outcomes (RR, 1.26; 95% CI, 0.92-1.72) between the hypothermia and normothermia strategies. Similarly, no difference was observed in mortality (RR, 1.00; 95% CI, 0.97-1.03) or neurologic outcome (RR, 0.96; 95% CI, 0.85-1.08) between the prehospital hypothermia versus in-hospital hypothermia strategies. CONCLUSIONS: Our results suggest that TTM with therapeutic hypothermia may not improve mortality or neurologic outcomes in postarrest survivors. Using therapeutic hypothermia as a standard of care strategy of postarrest care in survivors may need to be reevaluated.
Authors: Rajat Kalra; Pankaj Arora; Charity Morgan; Fadi G Hage; Ami E Iskandrian; Navkaranbir S Bajaj Journal: J Nucl Cardiol Date: 2016-08-02 Impact factor: 5.952
Authors: Stephen A Bernard; Karen Smith; Peter Cameron; Kevin Masci; David McD Taylor; D Jamie Cooper; Anne-Maree Kelly; William Silvester Journal: Crit Care Med Date: 2012-03 Impact factor: 7.598
Authors: Stephen A Bernard; Karen Smith; Judith Finn; Cindy Hein; Hugh Grantham; Janet E Bray; Conor Deasy; Michael Stephenson; Teresa A Williams; Lahn D Straney; Deon Brink; Richard Larsen; Chris Cotton; Peter Cameron Journal: Circulation Date: 2016-08-25 Impact factor: 29.690
Authors: Tom P Aufderheide; Rajat Kalra; Marinos Kosmopoulos; Jason A Bartos; Demetris Yannopoulos Journal: Ann N Y Acad Sci Date: 2021-02-20 Impact factor: 5.691
Authors: Hiren R Modi; Qihong Wang; Sarah J Olmstead; Elizabeth S Khoury; Nirnath Sah; Yu Guo; Payam Gharibani; Rishi Sharma; Rangaramanujam M Kannan; Sujatha Kannan; Nitish V Thakor Journal: Bioeng Transl Med Date: 2021-10-13